00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
18:33 , Jul 27, 2017 |  BC Innovations  |  Translation in Brief

Cycling across the membrane

In a Nature Chemistry study, a German team has shown that nanobodies coupled to cyclic peptides rich in arginine can target intracellular proteins with antibody-like precision and even deliver extracellular proteins to the cytosol. Delivering proteins...
19:06 , Jan 6, 2017 |  BioCentury  |  Emerging Company Profile

Gobbling globulins

Syntimmune Inc. is targeting a receptor that mediates the life span and activity of immunoglobulin G to control autoimmune disease more precisely and potentially more safely than broadly acting agents. The company aims to differentiate...
22:07 , Dec 30, 2016 |  BC Week In Review  |  Company News

Harbour BioMed, Harbour Antibodies deal

Harbour BioMed acquired Harbour Antibodies for an undisclosed upfront payment and equity investment. Harbour Antibodies’ H2L2 transgenic mouse platform generates human IgG mAbs with two heavy chain and two light chain immunoglobulins, and its HCAb...
11:41 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Blisibimod: Ph III CHABLIS-SC1 data

Top-line data from the double-blind, international Phase III CHABLIS-SC1 trial in about 442 patients with SLE despite ongoing stable corticosteroid therapy showed that once-weekly subcutaneous blisibimod missed the primary endpoint of a greater proportion of...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Quest Pharma, Shenzhen Hepalink Pharmaceutical deal

Quest’s OncoQuest Inc. subsidiary and Hepalink formed newco OncoVent Co. Ltd. to develop immunotherapies for cancer in China. Hepalink will own 54% of OncoVent’s shares, and Quest PharmaTech and OncoQuest will own 46%. The...
08:00 , Dec 7, 2015 |  BioCentury  |  Regulation

Action in amyloidosis

The Amyloidosis Research Consortium is following in the footsteps of another well-organized rare disease community by drafting a proposed FDA guidance that will reflect patients' priorities. The advocacy group also plans to qualify a cardiac...
08:00 , Dec 3, 2015 |  BC Innovations  |  Product R&D

Microbiome at the checkpoint

The growing belief that the microbiome can be harnessed to treat cancer has arguably received its biggest boost to date with the publication of two papers in Science linking two of the hottest targets in...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

CD19 CAR T cells: Phase I/IIa data

Data from 11 patients with relapsed or refractory CD19-positive B cell malignancies in an open-label, Swedish Phase I/IIa trial showed that the university’s CD19 CAR T cells led to 6 complete responses. Two of the...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

Revolade eltrombopag regulatory update

The European Commission approved Revolade eltrombopag from Novartis to treat severe aplastic anemia ( SAA) in adults who were either refractory to prior immunosuppressive therapy (IST) or heavily pretreated and are unsuitable for hematopoietic stem...